Lipella Pharmaceuticals Common Stock Price Patterns
| LIPO Stock | 0.23 0.06 35.29% |
Momentum 39
Sell Extended
Oversold | Overbought |
Wall Street Target Price 10 | Quarterly Revenue Growth (0.36) |
Using Lipella Pharmaceuticals hype-based prediction, you can estimate the value of Lipella Pharmaceuticals Common from the perspective of Lipella Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Lipella Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Lipella because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Lipella Pharmaceuticals after-hype prediction price | USD 0.22 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Lipella Pharmaceuticals Basic Forecasting Models to cross-verify your projections. Lipella Pharmaceuticals After-Hype Price Density Analysis
As far as predicting the price of Lipella Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Lipella Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Lipella Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Lipella Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Lipella Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Lipella Pharmaceuticals' historical news coverage. Lipella Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.01 and 10.98, respectively. We have considered Lipella Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Lipella Pharmaceuticals is extremely dangerous at this time. Analysis and calculation of next after-hype price of Lipella Pharmaceuticals is based on 3 months time horizon.
Lipella Pharmaceuticals Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Lipella Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lipella Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Lipella Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.53 | 10.76 | 0.01 | 0.00 | 21 Events / Month | 7 Events / Month | In about 21 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.23 | 0.22 | 4.35 |
|
Lipella Pharmaceuticals Hype Timeline
Lipella Pharmaceuticals is now traded for 0.23. The entity has historical hype elasticity of -0.01, and average elasticity to hype of competition of 0.0. Lipella is projected to decline in value after the next headline, with the price expected to drop to 0.22. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -4.35%, whereas the daily expected return is now at -0.53%. The volatility of related hype on Lipella Pharmaceuticals is about 134500.0%, with the expected price after the next announcement by competition of 0.23. The company has price-to-book ratio of 0.53. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lipella Pharmaceuticals recorded a loss per share of 3.33. The entity had not issued any dividends in recent years. The firm had 1:8 split on the 8th of November 2024. Given the investment horizon of 90 days the next projected press release will be in about 21 days. Check out Lipella Pharmaceuticals Basic Forecasting Models to cross-verify your projections.Lipella Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Lipella Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Lipella Pharmaceuticals' future price movements. Getting to know how Lipella Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Lipella Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PTIX | Protagenic Therapeutics | 0.15 | 7 per month | 0.00 | (0.20) | 14.81 | (15.25) | 58.73 | |
| GTBP | GT Biopharma | (0.07) | 8 per month | 6.74 | 0.03 | 10.84 | (10.45) | 51.03 | |
| AZTR | Azitra Inc | 0.00 | 7 per month | 0.00 | (0.15) | 7.14 | (11.36) | 34.09 | |
| ARTL | Artelo Biosciences | 0.43 | 7 per month | 0.00 | (0.09) | 7.86 | (11.25) | 43.34 | |
| NKGN | NKGen Biotech Common | 0.00 | 0 per month | 0.00 | 0.21 | 20.00 | (6.00) | 68.90 | |
| SLRX | Salarius Pharmaceuticals | (0.02) | 6 per month | 0.00 | (0.19) | 16.00 | (16.92) | 61.05 | |
| DRMA | Dermata Therapeutics | (0.32) | 10 per month | 0.00 | (0.05) | 16.18 | (12.50) | 58.17 | |
| VRAX | Virax Biolabs Group | (0.01) | 8 per month | 0.00 | (0.07) | 7.89 | (10.20) | 92.80 | |
| INDP | Indaptus Therapeutics | 0.01 | 6 per month | 0.00 | (0.06) | 13.58 | (12.56) | 51.64 | |
| PBM | Psyence Biomedical Ltd | (0.09) | 17 per month | 0.00 | (0.23) | 9.41 | (13.79) | 96.66 |
Lipella Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Lipella price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Lipella using various technical indicators. When you analyze Lipella charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Lipella Pharmaceuticals Predictive Indicators
The successful prediction of Lipella Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Lipella Pharmaceuticals Common, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Lipella Pharmaceuticals based on analysis of Lipella Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Lipella Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Lipella Pharmaceuticals's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Current Ratio | 8.9 | 3.47 | 3.12 | 3.56 | Net Debt To EBITDA | 0.69 | 0.43 | 0.49 | 0.47 |
Pair Trading with Lipella Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipella Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Lipella Stock
| 0.81 | EVGN | Evogene | PairCorr |
| 0.7 | IMNN | Imunon Inc | PairCorr |
| 0.64 | IPHA | Innate Pharma | PairCorr |
| 0.69 | LYRA | Lyra Therapeutics | PairCorr |
| 0.79 | MBIO | Mustang Bio | PairCorr |
Moving against Lipella Stock
| 0.88 | ARWR | Arrowhead Pharmaceuticals | PairCorr |
| 0.83 | MRKR | Marker Therapeutics | PairCorr |
| 0.74 | CING | Cingulate | PairCorr |
| 0.62 | AEON | AEON Biopharma | PairCorr |
| 0.61 | CRDF | Cardiff Oncology Buyout Trend | PairCorr |
| 0.55 | BOLT | Bolt Biotherapeutics | PairCorr |
The ability to find closely correlated positions to Lipella Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipella Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipella Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipella Pharmaceuticals Common to buy it.
The correlation of Lipella Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipella Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipella Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipella Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Lipella Pharmaceuticals Basic Forecasting Models to cross-verify your projections. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Will Biotechnology sector continue expanding? Could Lipella diversify its offerings? Factors like these will boost the valuation of Lipella Pharmaceuticals. Expected growth trajectory for Lipella significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lipella Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.33) | Revenue Per Share | Quarterly Revenue Growth (0.36) | Return On Assets | Return On Equity |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Lipella Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lipella Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Lipella Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.